A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 diabetes who want an alternative to using an insulin pump or multiple daily injections (MDI) for insulin delivery.